27547432|t|Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis
27547432|a|The presence of myocardial fibrosis by cardiac MRI has prognostic value in cardiac sarcoidosis, and localisation may be equally relevant to clinical outcomes. We aimed to analyse cardiac damage and function in detail and explore the relationship with clinical outcomes in patients with cardiac sarcoidosis using cardiac MRI. We included 81 consecutive patients with cardiac sarcoidosis undergoing cardiac MR. Left ventricular mass and fibrosis mass were calculated, and localisation was analysed using a 17-segment model. Participants underwent follow-up through 2015, and the development of major adverse cardiac events including ventricular tachyarrhythmias was recorded. Increased left ventricular fibrosis mass was associated with increased prevalence of ventricular tachyarrhythmias (p<0.001). When localisation was defined as the sum of late gadolinium enhancement in the left ventricular basal anterior and basal anteroseptal area s, or the right ventricular area, it was associated with ventricular tachyarrhythmias (p<0.001). Kaplan-Meier analysis during a median follow-up of 22.1 months showed that both the mass and localisation groupings for fibrosis were significantly associated with major adverse cardiac events or ventricular tachyarrhythmias and that when combined, the risk stratification was better than for each variable alone (p<0.001, respectively). By Cox-proportional hazard risk analysis, the localisation grouping was an independent predictor for the both. In patients with cardiac sarcoidosis, both fibrosis mass and its localisation to the basal anterior / anteroseptal left ventricle, or right ventricle was associated with the development of major adverse cardiac events or ventricular tachyarrhythmias. Cardiac MR with late gadolinium enhancement may be useful for improving risk stratification in patients with cardiac sarcoidosis.
27547432	0	4	Risk	T078	C0035647
27547432	5	19	stratification	T062	C1514983
27547432	24	29	major	T080	C0205164
27547432	30	52	adverse cardiac events	T033	C1556247
27547432	57	85	ventricular tachyarrhythmias	T047	C0042514
27547432	89	100	cardiac MRI	T060	C0412692
27547432	104	112	patients	T101	C0030705
27547432	118	137	cardiac sarcoidosis	T047	C0392077
27547432	154	173	myocardial fibrosis	T046	C0151654
27547432	177	188	cardiac MRI	T060	C0412692
27547432	193	209	prognostic value	T201	C1514474
27547432	213	232	cardiac sarcoidosis	T047	C0392077
27547432	238	250	localisation	T169	C0475264
27547432	266	274	relevant	T080	C2347946
27547432	278	295	clinical outcomes	T033	C0243095
27547432	317	331	cardiac damage	T033	C3844005
27547432	336	344	function	T042	C0232164
27547432	389	406	clinical outcomes	T033	C0243095
27547432	410	418	patients	T101	C0030705
27547432	424	443	cardiac sarcoidosis	T047	C0392077
27547432	450	461	cardiac MRI	T060	C0412692
27547432	478	489	consecutive	T080	C1707491
27547432	490	498	patients	T101	C0030705
27547432	504	523	cardiac sarcoidosis	T047	C0392077
27547432	535	545	cardiac MR	T060	C0412692
27547432	547	568	Left ventricular mass	T033	C0455825
27547432	573	581	fibrosis	T046	C0016059
27547432	582	586	mass	T033	C0577559
27547432	608	620	localisation	T169	C0475264
27547432	642	658	17-segment model	T075	C0026336
27547432	660	672	Participants	T098	C0679646
27547432	683	692	follow-up	T058	C1522577
27547432	715	726	development	T169	C1527148
27547432	730	735	major	T080	C0205164
27547432	736	758	adverse cardiac events	T033	C1556247
27547432	769	797	ventricular tachyarrhythmias	T047	C0042514
27547432	812	821	Increased	T081	C0205217
27547432	822	838	left ventricular	T023	C0225897
27547432	839	847	fibrosis	T046	C0016059
27547432	848	852	mass	T033	C0577559
27547432	873	882	increased	T081	C0205217
27547432	883	893	prevalence	T081	C0220900
27547432	897	925	ventricular tachyarrhythmias	T047	C0042514
27547432	942	954	localisation	T169	C0475264
27547432	981	1008	late gadolinium enhancement	T130	C3249258
27547432	1016	1047	left ventricular basal anterior	T023	C4288836
27547432	1052	1075	basal anteroseptal area	T023	C4288834
27547432	1086	1108	right ventricular area	T023	C0456871
27547432	1133	1161	ventricular tachyarrhythmias	T047	C0042514
27547432	1173	1194	Kaplan-Meier analysis	T081	C1720943
27547432	1204	1210	median	T081	C0876920
27547432	1211	1220	follow-up	T058	C1522577
27547432	1257	1261	mass	T033	C0577559
27547432	1266	1278	localisation	T169	C0475264
27547432	1293	1301	fibrosis	T046	C0016059
27547432	1337	1342	major	T080	C0205164
27547432	1343	1365	adverse cardiac events	T033	C1556247
27547432	1369	1397	ventricular tachyarrhythmias	T047	C0042514
27547432	1426	1430	risk	T078	C0035647
27547432	1431	1445	stratification	T062	C1514983
27547432	1450	1456	better	T080	C0332272
27547432	1514	1551	Cox-proportional hazard risk analysis	T081,T170	C0010235
27547432	1557	1569	localisation	T169	C0475264
27547432	1570	1578	grouping	T169	C1522242
27547432	1586	1597	independent	T033	C1299583
27547432	1598	1607	predictor	T078	C2698872
27547432	1625	1633	patients	T101	C0030705
27547432	1639	1658	cardiac sarcoidosis	T047	C0392077
27547432	1665	1673	fibrosis	T046	C0016059
27547432	1674	1678	mass	T033	C0577559
27547432	1687	1699	localisation	T169	C0475264
27547432	1707	1721	basal anterior	T023	C0555926
27547432	1724	1751	anteroseptal left ventricle	T023	C1300766
27547432	1756	1771	right ventricle	T023	C0456871
27547432	1796	1807	development	T169	C1527148
27547432	1811	1816	major	T080	C0205164
27547432	1817	1839	adverse cardiac events	T033	C1556247
27547432	1843	1871	ventricular tachyarrhythmias	T047	C0042514
27547432	1873	1883	Cardiac MR	T060	C0412692
27547432	1889	1916	late gadolinium enhancement	T130	C3249258
27547432	1935	1944	improving	T080	C1272745
27547432	1945	1949	risk	T078	C0035647
27547432	1950	1964	stratification	T062	C1514983
27547432	1968	1976	patients	T101	C0030705
27547432	1982	2001	cardiac sarcoidosis	T047	C0392077